Guobang Pharma Ltd (605507) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.038x

Based on the latest financial reports, Guobang Pharma Ltd (605507) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥311.27 Million ≈ $45.55 Million USD) by net assets (CN¥8.28 Billion ≈ $1.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 605507 net asset quality score to measure how much of total assets are equity-financed.

Guobang Pharma Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Guobang Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 605507 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Guobang Pharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guobang Pharma Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Labrador Iron Ore Royalty Corp TO:LIF	0.051x
Jamieson Wellness Inc TO:JWEL	0.014x
immatics biotechnologies GmbH F:4A3	-0.121x
SYoung Group Co Ltd SHE:300740	0.010x
Via Transportation, Inc. NASDAQ:VIA	-0.034x
Alexanders Inc NYSE:ALX	0.075x
secunet Security Networks Aktiengesellschaft F:YSN	-0.009x
Henan Zhongyuan Expressway Co Ltd SHG:600020	0.063x

Annual Cash Flow Conversion Efficiency for Guobang Pharma Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Guobang Pharma Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Guobang Pharma Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥8.56 Billion ≈ $1.25 Billion	CN¥559.28 Million ≈ $81.84 Million	0.065x	-25.49%
2024-12-31	CN¥8.05 Billion ≈ $1.18 Billion	CN¥706.41 Million ≈ $103.37 Million	0.088x	+26.26%
2023-12-31	CN¥7.44 Billion ≈ $1.09 Billion	CN¥516.76 Million ≈ $75.62 Million	0.069x	-51.12%
2022-12-31	CN¥7.15 Billion ≈ $1.05 Billion	CN¥1.02 Billion ≈ $148.82 Million	0.142x	+611.99%
2021-12-31	CN¥6.35 Billion ≈ $928.57 Million	CN¥-176.18 Million ≈ $-25.78 Million	-0.028x	-111.84%
2020-12-31	CN¥3.27 Billion ≈ $479.11 Million	CN¥767.70 Million ≈ $112.34 Million	0.234x	+39.13%
2019-12-31	CN¥2.62 Billion ≈ $382.78 Million	CN¥440.86 Million ≈ $64.51 Million	0.169x	-19.35%
2018-12-31	CN¥2.59 Billion ≈ $379.31 Million	CN¥541.68 Million ≈ $79.27 Million	0.209x	+211.60%
2017-12-31	CN¥2.21 Billion ≈ $323.00 Million	CN¥148.03 Million ≈ $21.66 Million	0.067x	--

About Guobang Pharma Ltd

SHG:605507 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.26 Billion

CN¥8.59 Billion CNY

Market Cap Rank

#7918 Global

#1802 in China

Share Price

CN¥15.37

Change (1 day)

-3.33%

52-Week Range

CN¥14.70 - CN¥29.25

All Time High

CN¥43.71